# Pharmaceuticals
Latest news and articles about Pharmaceuticals
Total: 11 articles found
From Gold Mine to Glut: The Darkest Hour for China’s HPV Vaccine Giants
China's leading HPV vaccine manufacturers, Wantai and Zhifei, have reported record financial losses as the market shifts from scarcity to a massive oversupply. A combination of high vaccination rates among wealthy demographics and aggressive government price-cutting has collapsed profit margins, forcing a difficult strategic pivot.
Eli Lilly Bets $7 Billion on the ‘Holy Grail’ of Cancer Therapy to Diversify Beyond Weight Loss
Eli Lilly is acquiring Kelonia Therapeutics for up to $7 billion to gain access to its revolutionary in-vivo CAR-T technology. This strategic move aims to diversify Lilly's portfolio beyond its successful weight-loss business and establish a leading position in the high-growth oncology market.
China’s Tech-Heavy ChiNext Retreats After Testing Decade-Highs Amid Profit-Taking
China's ChiNext index hit its highest level since the 2015 bubble before reversing sharply to close down over 1%. Despite a massive 2.42 trillion yuan turnover, the market saw widespread declines, though pharmaceutical and AI-leasing stocks bucked the downward trend.
China’s Pharma Roadmap: Beijing Unveils Strategic Pivot to High-Value Innovation and AI Integration
China's MIIT has announced the framework for the 15th Five-Year Plan for the pharmaceutical industry, focusing on accelerating drug innovation, lowering prices through AI integration, and addressing the needs of elderly and rare-disease patients. The policy aims to balance industrial growth with public affordability while positioning Chinese biotech as a competitive global force.
Neural Rewiring: Shanghai Biotech Secures Global First with Dual US-China Approval for Epilepsy Cell Therapy
Shanghai's Yuesai Biotechnology has become the first company globally to receive IND approval from both the US FDA and China's CDE for an iPSC-derived cell therapy targeting refractory epilepsy, marking a major breakthrough in regenerative medicine.
The 100% Bluff: Why Washington’s Radical Drug Tariff May Never Be Collected
The U.S. government’s announcement of a 100% tariff on imported drugs is essentially a tactical negotiation tool rather than a fiscal reality. Through a series of 'Most Favored Nation' deals and manufacturing incentives, the administration is using the threat of high tariffs to force global drugmakers into domestic investment and lower pricing.
A Bitter Pill: Trump’s 100% Drug Tariffs and the Future of Chinese Biotech
President Trump has signed an executive order under Section 232 to impose 100% tariffs on imported patent drugs and APIs, aimed at forcing price concessions and manufacturing onshoring. While Chinese biotech firms face new challenges, many are already pivoting toward U.S.-based production to mitigate these trade risks.
Cracks in the Citadel: One Year After Trump’s ‘Liberation Day,’ the Cost of Isolationism Mounts
One year after the 'Liberation Day' tariff overhaul, the Trump administration has introduced 100% tariffs on pharmaceuticals and unified 25% levies on metal derivatives. These aggressive moves have accelerated a global shift away from U.S. assets and imposed multi-billion dollar costs on domestic automakers, failing to resolve underlying fiscal deficits.
Policy Tailwinds and Tech Optimism Drive China’s Markets to a Strong Second-Quarter Start
China's major stock indices surged over 1% in the first session of the second quarter, led by a 3% jump in the tech-heavy STAR 50. The rally was driven by the pharmaceutical sector and new energy storage policies, even as traditional infrastructure stocks faced a sell-off.
China’s Oncology Frontier: Bioken’s Breakthrough Signals New Global Standard in Lung Cancer Treatment
Chinese biotech firm Bioken has reported record-breaking Phase II clinical results for its bispecific ADC lung cancer treatment, achieving a 100% tumor shrinkage rate in target lesions. Backed by a historic $8.4 billion deal with Bristol Myers Squibb, the company’s success highlights China’s rapid ascent from a generic drug producer to a leader in original pharmaceutical innovation.
A Veteran’s Departure: The Executive Exit Signaling a Crisis in China’s Vaccine Market
The resignation of Wantai Biological’s 20-year veteran board secretary, Yu Tao, underscores a deep crisis in China's vaccine sector. As domestic price wars slash HPV vaccine prices by 90%, the former industry leader is facing massive losses and a desperate pivot toward international markets.